Despite increased use and sales of statins in India, per capita prescription rates remain far below high-income countries

Health Affairs

Volumn 33, Issue 2, 2014, Pages 273-282

  Choudhry, Niteesh K ^a,b   Dugani, Sagar ^b   Shrank, William H ^b   Polinski, Jennifer M ^b   Stark, Christina E ^b,c   Gupta, Rajeev ^d   Prabhakaran, Dorairaj ^e   Brill, Gregory ^b   Jha, Prabhat ^f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c YALE UNIVERSITY SCHOOL OF NURSING   (United States)

^d FORTIS HOSPITAL   (India)

^e PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^f Centre for Global Health Research   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CULTURAL ANTHROPOLOGY; DRUG COST; DRUG MARKETING; DRUG USE; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; INCOME; INDIA; ISCHEMIC HEART DISEASE; OBSERVATIONAL STUDY; PRESCRIPTION; AGED; COMPARATIVE STUDY; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG UTILIZATION; ECONOMICS; FEMALE; MALE; MIDDLE AGED; NEEDS ASSESSMENT; NORTH AMERICA; RETROSPECTIVE STUDY; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA;

AGED; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DRUG UTILIZATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCOME; INDIA; MALE; MIDDLE AGED; NEEDS ASSESSMENT; NORTH AMERICA; PRESCRIPTIONS; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS;

EID: 84893575657     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2013.0388     Document Type: Article

References (63)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78.
2. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166(21):2307-13.
3. Choudhry NK. Improving the pathway from cardiovascular medication prescribing to longer-term adherence: new results about old issues. Circ Cardiovasc Qual Outcomes. 2010;3(3):223-5.
4. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet. 2011;377(9765): 578-86.
5. Wijeysundera HC, Machado M, Farahati F,Wang X,Witteman W, van der Velde G, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA. 2010;303(18):1841-7.
6. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007; 356(23):2388-98.
7. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104(22): 2746-53.
8. Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease andstroke in India. Heart. 2008;94(1): 16-26.
9. Gaziano TA. Cardiovascular disease in the developing world and its costeffective management. Circulation. 2005;112(23):3547-53.
10. Patel V, Chatterji S, Chisholm D, Ebrahim S, Gopalakrishna G, Mathers C, et al. Chronic diseases and injuries in India. Lancet. 2011;377(9763):413-28.
11. Gagne JJ, Choudhry NK. How many "me-too" drugs is too many? JAMA. 2011;305(7):711-2.
12. Chokshi DA, Rajkumar R. Leveraging university research to advance global health. JAMA. 2007;298(16): 1934-6.
13. Kesselheim AS, Choudhry NK. The international pharmaceutical market as a source of low-cost prescription drugs for U.S. patients. Ann Intern Med. 2008;148(8):614-9.
14. Jeffery R. Pharmaceuticals distribution systems in India. Edinburgh: University of Edinburgh, Centre for International Public Health Policy; 2007.
15. Kelkar A, Langer ES. Pharmaceutical distribution in India. BioPharm International [serial on the Internet]. 2008 Oct 1 [cited 2014 Jan 8]. Available from: http://www.biopharminternational.com/biopharm/article/articleDetail.jsp?id=557245&sk=&date=&pageID=3
16. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment: 2011 [Internet]. Oslo: WHOCC; 2010 [cited 2011 Jan 13]. Available from: http://www.whocc.no/filearchive/publications/2011guidelines.pdf
17. Government of India, Central Bureau of Health Intelligence. National health profile (NHP) of India-2009. New Delhi: The Bureau; [cited 2014 Jan 8]. Available from: http://cbhidghs.nic.in/index2.asp?slid=1068&sublinkid=721
18. Government of India, Ministry of Health and FamilyWelfare. Report of the National Commission on Macroeconomics and Health [Internet]. New Delhi: The Ministry; 2005 Sep [cited 2014 Jan 8]. Available from: http://www.who.int/macrohealth/action/Report%20of%20the%20National%20Commission.pdf
19. Indrayan A. Forecasting vascular disease cases and associated mortality in India [Internet]. Delhi: University College of Medical Sciences, Division of Biostatistics and Medical Informatics; [cited 2014 Jan 8]. (NCMH Background Papers-Burden of Disease in India). Available from: http://www.searo.who.int/india/topics/cardiovascular_diseases/Commision_on_Macroeconomic_and_Health_Bg_P2_Forecasting_vascular_disease_cases_and_associated_mortality_in_India.pdf
20. Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care. 2001; 24(11):1936-40.
21. To access the Appendix, click on the Appendix link in the box to the right of the article online
22. Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of ezetimibe in the United States and Canada. N Engl J Med. 2008;358(17):1819-28.
23. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167(6):540-9.
24. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404): 1419.
25. Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS One. 2012;7(7):e41297.
26. Central Drugs Standard Control Organization [home page on the Internet]. New Delhi: CDSCO; [cited 2014 Jan 13]. Available from: http://www.cdsco.nic.in/
27. Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373(9672): 1341-51.
28. Xavier D, Pais P, Sigamani A, Pogue J, Afzal R, Yusuf S. The need to test the theories behind the polypill: rationale behind the Indian Polycap Study. Nat Clin Pract Cardiovasc Med. 2009;6(2):96-7.
29. Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310(9): 918-29.
30. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585-90.
31. Ginsberg HN, Elam MB, Lovato LC, Crouse JR , Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-74.
32. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431-43.
33. National Institutes of Health. NIH stops clinical trial on combination cholesterol treatment [Internet]. Bethesda (MD): NIH; 2011 May 26 [cited 2014 Jan]. Available from: http://www.nih.gov/news/health/may2011/nhlbi-26.htm
34. Central Drugs Standard Control Organization. Guidance for industry on fixed dose combinations (FDCS) [Internet]. New Delhi: CDSCO; 2010 Aug 20 [cited 2014 Jan 13]. Available from: http://cdsco.nic.in/FDC%20Guidelines%20_%20Revised1.pdf
35. Singal GL, Nanda A, Kotwani A. A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India. Indian J Pharmacol. 2011;43(2):131-6.
36. Food and Drug Administration [Internet]. Silver Spring (MD): FDA. Press release, Pfizer announces voluntary nationwide recall of Lo/ Ovralfi-28 and Norgestrel/Ethinyl Estradiol tablets due to possibility of inexact tablet counts or out of sequence tablets. 2012 Jan 31 [cited 2014 Jan 8]. Available from: http://www.fda.gov/Safety/Recalls/ucm289770.htm?source=govdelivery
37. Drug regulation in India-the time is ripe for change. Lancet. 2012; 379(9829):1862.
38. Department-Related Parliamentary Standing Committee on Health and Family Welfare. Fifty-ninth report on the functioning of the Central Drugs Standard Control Organisation (CDSCO) [Internet]. New Delhi: Parliament of India Rajya Sabha; 2012 May [cited 2014 Jan 8]. Available from: http://www.elsevierbi.com/~/media/Supporting%20Documents/Pharmasia%20News/2012/May/DCGI%20report.pdf
39. Gautam CS, Utreja A, Singal GL. Spurious and counterfeit drugs: a growing industry in the developing world. Postgrad Med J. 2009; 85(1003):251-6.
40. IMS Institute for Healthcare Informatics. The use of medicines in the United States: review of 2010 [Internet]. Parsippany (NJ): The Institute; 2011 Apr [cited 2014 Jan 8]. Available from: http://www.imshealth.com/imshealth/Global/Content/IMSInstitute/Documents/IHII_UseOfMed_report.pdf
41. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-9.
42. Goyal R, Pareek P. A review article on prescription behavior of doctors, influenced by the medical representative in Rajasthan, India. IOSR Journal of Business and Management. 2013;8(1):56-60.
43. Bansal R, Das S. Unethical relationship between doctors and drug companies. Journal of Indian Academy of Forensic Medicine. 2005; 27(1):40-2.
44. Patel J. The gifts and trinkets to doctors: current practice in India and global trends in pharmaceutical industry. Bombay Hosp J. 1992;34: 1177-84.
45. Roy N, Madhiwalla N, Pai SA. Drug promotional practices in Mumbai: a qualitative study. Indian J Med Ethics. 2007;4(2):57-61.
46. Greenhalgh T. Drug marketing in the Third World: beneath the cosmetic reforms. Lancet. 1986; 1(8493):1318-20.
47. Lodha R, Bhargava A. Financial incentives and the prescription of newer vaccines by doctors in India. Indian J Med Ethics. 2010;7(1): 28-30.
48. Bhaumik S. Medical regulator urges doctors to prescribe generic drugs. BMJ. 2013;346:f564.
49. Mudur G. India's capping of drug prices will leave drugs costing near the market price. BMJ. 2012;345: e6649.
50. Nagral S, Roy N. The Medical Council of India guidelines on industry-physician relationship: breaking the conspiracy of silence. Natl Med J India. 2010;23(2):69-71.
51. Xavier D, Pais P, Devereaux PJ, Xie C, Prabhakaran D, Reddy KS, et al. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet. 2008; 371(9622):1435-42.
52. Sharma KK, Gupta R, Agrawal A, Roy S, Kasliwal A, Bana A, et al. Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India. Vasc Health Risk Manag. 2009;5: 1007-14.
53. Joshi R, Chow CK, Raju PK, Raju R, Reddy KS, Macmahon S, et al. Fatal and nonfatal cardiovascular disease and the use of therapies for secondary prevention in a rural region of India. Circulation. 2009;119(14): 1950-5.
54. Srinivas G, Suresh E, Jagadeesan M, Amalraj E, Datta M. Treatmentseeking behavior and compliance of diabetic patients in a rural area of south India. Ann N Y Acad Sci. 2002;958:420-4.
55. Bowry AD, Shrank WH, Lee JL, Stedman M, Choudhry NK. A systematic review of adherence to cardiovascular medications in resourcelimited settings. J Gen Intern Med. 2011;26(12):1479-91.
56. Choudhry NK, Shrank WH. Fourdollar generics-increased accessibility, impaired quality assurance. N Engl J Med. 2010;363(20):1885-7.
57. World Bank. GNI per capita, Atlas method (current US$) [Internet]. Washington (DC): World Bank; [cited 2014 Jan 8]. Available from: http://data.worldbank.org/indicator/NY.GNP.PCAP.CD
58. Deolalikar AB, Jamison DT, Jha P, Laxminarayan R. Financing health improvements In India. Health Aff (Millwood). 2008;27(4):978-90.
59. Selvaraj S, Karan AP.Why publiclyfinanced health insurance schemes are ineffective in providing financial risk protection. Econ Polit Wkly. 2012;47(11):60-8.
60. Dilip TR. On publicly-financed health insurance schemes-is the analysis premature? Econ PolitWkly. 2012;47(18):79-80.
61. Salvaraj S. Publicly-tinanced health insurance schemes. Ignorance is not bliss. Econ Polit Wkly. 2012;47(29): 109-11.
62. Government of India, National Pharmaceutical Pricing Authority [home page on the Internet]. New Delhi: The Authority; [cited 2014 Jan 8]. Available from: http://www.nppaindia.nic.in/index1.html
63. Lee TH. Eulogy for a quality measure. N Engl J Med. 2007;357(12): 1175-7.